MERIAL: RECOMBITEK® Oral Bordetella Vaccine | Boehringer Ingelheim US
MERIAL, now part of Boehringer Ingelheim, grows canine vaccine portfolio with the introduction of the RECOMBITEK® Oral Bordetella vaccine.
Search
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
BI Beyond Borders: Science, Collaboration, Geography | BI US
Read more on how the Company’s ‘radar’ for the next big wave of innovation, the RBB team, is tasked with exploring emerging science and technologies.
Talking drug discovery with our U.S. research site head, Carine Boustany
Learn about the challenges and victories of developing new medicine for conditions, like generalized pustular psoriasis (GPP) flares in adults.
Ordering your medicine online? Find a safe pharmacy first.
Learn what to look for when buying medication and how to verify your pharmacy.
Topline results from Boehringer's Phase III IPF Study
Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis
Expanded Access Programs
Expanded Access Programs
Discovery Research Global Post-Doc Program
Discovery Research Global Post-Doc Program
New Swine Vaccine Combination Released | Boehringer Ingelheim US
Click here to read more on the introduction of another new swine vaccination combination from Boehringer Ingelheim, protecting pigs from common viruses.
Improving Access to Clinical Trials
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
NVSS: The Future Vets & Scientists | Boehringer Ingelheim US
Click here to read more on the annual National Veterinary Scholars Symposium, celebrating future veterinarians and scientists across the USA.
Schizophrenia: Trial Results Show Advance in Cognition | BI US
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.
Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment
Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment
What to Expect from Your Vaccine | Boehringer Ingelheim US
Read more on how horse owners are encouraged to schedule a wellness exam with their veterinarians, including annual equine vaccinations.
From garage start-up to global pharma: combining strengths to advance regenerative medicine
Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.
Dr. Wolchinsky Receives Pioneer Award | Boehringer Ingelheim US
Read more about Dr. Steven Wolchinsky receiving the first Vetmedin® (pimobendan) Cardiology Pioneer award, for his work and commitment to animal health.
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Medicines reach record number of people, net sales rise
Protecting a Way of Life in Haiti | Boehringer Ingelheim US
Click here to find out how Boehringer Ingelheim is helping to protect a way of life in Haiti by producing a custom swine vaccine to support the island.
Technologies
We are expanding our global network of technology partners. Learn more about partnering with us.
Exploring T-cells in cancer
Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology, highlighting our investigational T-cell engagers platform and how we are driving innovation to potentially deliver meaningful advances to peop
Generalized pustular psoriasis: The importance of support and collaboration to promote advances in the GPP community
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
Clinical trials deliver medical breakthroughs – but how do they happen?
Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.
Schizophrenia in real life: Stories of resilience and hope
Discover the reality of life with schizophrenia through the stories of four people who are breaking down the stigma of living with a serious mental illness.
Poultry vaccine site in Georgia continues to reduce carbon emissions
Going carbon neutral has resulted in measurable, positive impacts. From 2021 to 2022, the Gainesville site reduced its CO2 emissions by 23 percent – nearly 700 fewer tons of CO2 emissions are released into the atmosphere
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics